Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple MyelomaJesús F. San Miguel, Hermann Einsele, Michèle Cavo et al.|New England Journal of Medicine|2023Cited by 719
CAR+ T-Cell Lymphoma Post Ciltacabtagene Autoleucel Therapy for Relapsed Refractory Multiple MyelomaSimon J. Harrison, Piers Blombery, Tamia Nguyen et al.|Blood|2023Cited by 99
CAR+ T-Cell Lymphoma after Cilta-cel Therapy for Relapsed or Refractory MyelomaSimon J. Harrison, Piers Blombery, Cyrille Touzeau et al.|New England Journal of Medicine|2025Cited by 58
Efficacy and Safety in Patients with Lenalidomide-Refractory Multiple Myeloma after 1-3 Prior Lines Who Received a Single Infusion of Ciltacabtagene Autoleucel As Study Treatment in the Phase 3 CARTITUDE-4 TrialM Hasib Sidiqi, Kwee Yong, Paolo Corradini et al.|Blood|2023Cited by 4
OA-45 Pharmacokinetic and correlative analysis of ciltacabtagene autoleucel in patients with lenalidomide-refractory multiple myeloma in the CARTITUDE-4 trialCarlos Fernández de Larrea, Christopher Strouse, Simon J. Harrison et al.|Clinical Lymphoma Myeloma & Leukemia|2023Cited by 3